Current Role of Radiotherapy for Renal-Cell Carcinoma: Review

Natalia Dengina; Ilya Tsimafeyeu; Timur Mitin

doi:10.1016/j.clgc.2016.09.004

Current Role of Radiotherapy for Renal-Cell Carcinoma: Review

Natalia Dengina, Ilya Tsimafeyeu, Timur Mitin

Knight Cancer Translational Oncology Program

Research output: Contribution to journal › Review article › peer-review

15 Scopus citations

Abstract

Surgery is the standard of care for patients with renal-cell carcinoma (RCC). Radiotherapy (RT) can decrease the risk of local recurrence after surgery and can lead to excellent outcomes in patients unfit for surgery. We reviewed clinical experience with various forms of RT, including conventional fractionated RT and intraoperative radiotherapy (IORT) as adjunct to surgery, hypofractionated high-dose stereotactic body radiotherapy (SBRT), and particle therapy in unresectable RCC. We discuss future directions for using RT in the treatment of RCC. We encourage clinicians to incorporate RT modalities in prospective clinical trials.

Original language	English (US)
Pages (from-to)	183-187
Number of pages	5
Journal	Clinical Genitourinary Cancer
Volume	15
Issue number	2
DOIs	https://doi.org/10.1016/j.clgc.2016.09.004
State	Published - Apr 1 2017

Keywords

Intraoperative radiotherapy
Particle therapy
Radioresistance
Radiosensitivity
Stereotactic body radiotherapy
Targeted therapy

ASJC Scopus subject areas

Oncology
Urology

Access to Document

10.1016/j.clgc.2016.09.004

Cite this

@article{da53974f3ae24617bc0c6ce75d09d6c4,

title = "Current Role of Radiotherapy for Renal-Cell Carcinoma: Review",

abstract = "Surgery is the standard of care for patients with renal-cell carcinoma (RCC). Radiotherapy (RT) can decrease the risk of local recurrence after surgery and can lead to excellent outcomes in patients unfit for surgery. We reviewed clinical experience with various forms of RT, including conventional fractionated RT and intraoperative radiotherapy (IORT) as adjunct to surgery, hypofractionated high-dose stereotactic body radiotherapy (SBRT), and particle therapy in unresectable RCC. We discuss future directions for using RT in the treatment of RCC. We encourage clinicians to incorporate RT modalities in prospective clinical trials.",

keywords = "Intraoperative radiotherapy, Particle therapy, Radioresistance, Radiosensitivity, Stereotactic body radiotherapy, Targeted therapy",

author = "Natalia Dengina and Ilya Tsimafeyeu and Timur Mitin",

note = "Publisher Copyright: {\textcopyright} 2016 Elsevier Inc.",

year = "2017",

month = apr,

day = "1",

doi = "10.1016/j.clgc.2016.09.004",

language = "English (US)",

volume = "15",

pages = "183--187",

journal = "Clinical Genitourinary Cancer",

issn = "1558-7673",

publisher = "Elsevier",

number = "2",

}

TY - JOUR

T1 - Current Role of Radiotherapy for Renal-Cell Carcinoma

T2 - Review

AU - Dengina, Natalia

AU - Tsimafeyeu, Ilya

AU - Mitin, Timur

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Surgery is the standard of care for patients with renal-cell carcinoma (RCC). Radiotherapy (RT) can decrease the risk of local recurrence after surgery and can lead to excellent outcomes in patients unfit for surgery. We reviewed clinical experience with various forms of RT, including conventional fractionated RT and intraoperative radiotherapy (IORT) as adjunct to surgery, hypofractionated high-dose stereotactic body radiotherapy (SBRT), and particle therapy in unresectable RCC. We discuss future directions for using RT in the treatment of RCC. We encourage clinicians to incorporate RT modalities in prospective clinical trials.

AB - Surgery is the standard of care for patients with renal-cell carcinoma (RCC). Radiotherapy (RT) can decrease the risk of local recurrence after surgery and can lead to excellent outcomes in patients unfit for surgery. We reviewed clinical experience with various forms of RT, including conventional fractionated RT and intraoperative radiotherapy (IORT) as adjunct to surgery, hypofractionated high-dose stereotactic body radiotherapy (SBRT), and particle therapy in unresectable RCC. We discuss future directions for using RT in the treatment of RCC. We encourage clinicians to incorporate RT modalities in prospective clinical trials.

KW - Intraoperative radiotherapy

KW - Particle therapy

KW - Radioresistance

KW - Radiosensitivity

KW - Stereotactic body radiotherapy

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85005993313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85005993313&partnerID=8YFLogxK

U2 - 10.1016/j.clgc.2016.09.004

DO - 10.1016/j.clgc.2016.09.004

M3 - Review article

C2 - 27789182

AN - SCOPUS:85005993313

SN - 1558-7673

VL - 15

SP - 183

EP - 187

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

IS - 2

ER -

Current Role of Radiotherapy for Renal-Cell Carcinoma: Review

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this